ImmunoTargets and Therapy

SJR Rank #4,114H-index: 36SJR: 1.110Best quartile: Q2Open AccessAPC: US$2,320Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

Dove Medical Press Ltd

Country

New Zealand

Type

journal

SJR by Edition

2022202500.450.91.351.8

Subject Categories

  • ImmunologyQ2
  • Immunology and AllergyQ2

Areas: Immunology and Microbiology · Medicine

Most published research topics

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy researchImmune Cell Function and InteractionImmune cells in cancerFerroptosis and cancer prognosisMonoclonal and Polyclonal Antibodies ResearchT-cell and B-cell ImmunologyHepatocellular Carcinoma Treatment and PrognosisImmune Response and Inflammation

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs0255075100

Documents per Year

202220250255075100

Detailed Information

ISSN

2253-1556

SJR Best Quartile

Q2

Region

Pacific Region

Citations per Document (2 years)

3.94

References per Document

81.71

Coverage

2015-2026

Scope

ImmunoTargets and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve patient management. Basic immunology and physiology of the immune system in health, and disease will be also covered. In addition, the journal will focus on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. This journal explores the evidence behind new and existing therapies in terms of improving outcomes and, importantly, will seek to define their usage in terms of ultimate uptake and acceptance by the patient and health care professional. As of 1st April 2019, ImmunoTargets and Therapy will no longer consider meta-analyses for publication.

Metrics from SCImago Journal Rank 2025. View on SCImago